Prevnar 13

Prevnar 13 is a pneumococcal conjugate vaccine developed by Wyeth, now part of Pfizer, to protect against Streptococcus pneumoniae serotypes. It is used to prevent pneumonia, meningitis, and sepsis caused by Streptococcus pneumoniae in children and adults, as recommended by the Centers for Disease Control and Prevention and the World Health Organization. The vaccine has been licensed in many countries, including the United States, Canada, and European Union member states, such as France, Germany, and Italy. It has been studied in various clinical trials, including those conducted by GlaxoSmithKline and Sanofi Pasteur, to evaluate its safety and efficacy.

Introduction

Prevnar 13 is a conjugate vaccine that combines the diphtheria toxin with Streptococcus pneumoniae serotypes to enhance immune response, as seen in other vaccines like Gardasil and Cervarix, developed by Merck & Co. and GlaxoSmithKline, respectively. The vaccine is administered via intramuscular injection, typically in a series of doses, as recommended by the American Academy of Pediatrics and the National Institute of Allergy and Infectious Diseases. Prevnar 13 has been used in vaccination programs in many countries, including Australia, Brazil, and China, to protect against Streptococcus pneumoniae infections. The vaccine has also been studied in conjunction with other vaccines, such as FluMist and Fluzone, developed by AstraZeneca and Sanofi Pasteur, respectively.

Mechanism_of_action

The mechanism of action of Prevnar 13 involves the induction of immune responses against the Streptococcus pneumoniae serotypes, as seen in other conjugate vaccines like Menactra and Menveo, developed by Sanofi Pasteur and Novartis, respectively. The vaccine contains diphtheria toxin as a carrier protein, which enhances the immune response to the Streptococcus pneumoniae serotypes, similar to the mechanism of Tetanus toxoid and Pertussis toxin. The immune response induced by Prevnar 13 involves the production of antibodies against the Streptococcus pneumoniae serotypes, which helps to prevent infection and disease caused by these serotypes, as seen in studies conducted by Harvard University and the University of Oxford. The vaccine has been shown to induce immune responses in children and adults, including those with immunodeficiency disorders, such as HIV/AIDS, as studied by the National Institutes of Health and the Bill and Melinda Gates Foundation.

Indications_and_usage

Prevnar 13 is indicated for use in children and adults to prevent pneumonia, meningitis, and sepsis caused by Streptococcus pneumoniae serotypes, as recommended by the Food and Drug Administration and the European Medicines Agency. The vaccine is typically administered in a series of doses, with the first dose given at 2 months of age and subsequent doses given at 4 months of age, 6 months of age, and 12-15 months of age, as recommended by the American Academy of Pediatrics and the Centers for Disease Control and Prevention. Prevnar 13 is also recommended for use in adults aged 50 years and older, as well as in adults with certain underlying medical conditions, such as chronic heart disease and chronic lung disease, as studied by the National Institute on Aging and the World Health Organization. The vaccine has been used in vaccination programs in many countries, including Canada, Australia, and Japan, to protect against Streptococcus pneumoniae infections.

Efficacy_and_effectiveness

The efficacy and effectiveness of Prevnar 13 have been evaluated in several clinical trials, including those conducted by Pfizer and GlaxoSmithKline. The vaccine has been shown to be highly effective in preventing pneumonia, meningitis, and sepsis caused by Streptococcus pneumoniae serotypes in children and adults, as seen in studies published in the New England Journal of Medicine and the Lancet. The vaccine has also been shown to be effective in preventing otitis media and pneumococcal conjugate vaccine-related invasive pneumococcal disease in children, as studied by the National Institute of Allergy and Infectious Diseases and the University of California, Los Angeles. Prevnar 13 has been used in conjunction with other vaccines, such as PCV10 and PPSV23, developed by GlaxoSmithKline and Merck & Co., respectively, to provide broader protection against Streptococcus pneumoniae infections.

Safety_and_side_effects

The safety and side effects of Prevnar 13 have been evaluated in several clinical trials, including those conducted by Pfizer and Sanofi Pasteur. The vaccine has been shown to be generally well-tolerated, with common side effects including pain, redness, and swelling at the injection site, as well as fever and irritability, as seen in studies published in the Journal of the American Medical Association and the British Medical Journal. Serious side effects, such as anaphylaxis and seizures, have been reported rarely, as studied by the Centers for Disease Control and Prevention and the World Health Organization. Prevnar 13 has been used in vaccination programs in many countries, including France, Germany, and Italy, to protect against Streptococcus pneumoniae infections, with ongoing monitoring of safety and side effects by organizations such as the European Medicines Agency and the Food and Drug Administration.

Manufacturing_and_distribution

Prevnar 13 is manufactured by Pfizer and distributed by the company and its partners, including GlaxoSmithKline and Sanofi Pasteur, to countries around the world, including United States, Canada, and European Union member states. The vaccine is typically stored in a refrigerator at a temperature between 2°C and 8°C and has a shelf life of up to 36 months, as recommended by the World Health Organization and the Centers for Disease Control and Prevention. Prevnar 13 is available in single-dose vials and pre-filled syringes, as well as in combination with other vaccines, such as PCV10 and PPSV23, developed by GlaxoSmithKline and Merck & Co., respectively. The vaccine has been used in vaccination programs in many countries, including Australia, Brazil, and China, to protect against Streptococcus pneumoniae infections, with ongoing monitoring of manufacturing and distribution by organizations such as the Food and Drug Administration and the European Medicines Agency. Category:Vaccines